Performance of DGX Quest Diagnostics | 23.4% in 12m
Compare DGX with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Quest Diagnostics with its related Sector/Index XLV
![Compare Quest Diagnostics with its related Sector/Index XLV](https://www.valueray.com/images/chart/DGX.NYSE_perf.png)
Performance Duell DGX vs XLV
TimeFrame | DGX | XLV |
---|---|---|
1 Week | -2.57% | -2.07% |
1 Month | 4.11% | 4.37% |
3 Months | 7.79% | 5.66% |
6 Months | 21.8% | 6.23% |
12 Months | 23.4% | 17.65% |
YTD | 10.4% | 11.77% |
Rel. Perf. 1m | -0.01 | |
Rel. Perf. 3m | 0.36 | |
Rel. Perf. 6m | 1.25 | |
Rel. Perf. 12m | 1.25 | |
Spearman 1m | 0.87 | 0.82 |
Spearman 3m | 0.92 | 0.89 |
Is Quest Diagnostics a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Quest Diagnostics (NYSE:DGX) is currently (September 2024)
ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 35.04 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DGX as of September 2024 is 157.39. This means that DGX is currently overvalued and has a potential downside of 2.92% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DGX as of September 2024 is 157.39. This means that DGX is currently overvalued and has a potential downside of 2.92% (Sold with Premium).
Is DGX a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 10
- Sell: 0
- Strong Sell: 0
Values above 0%: DGX is performing better - Values below 0%: DGX is underperforming
Compare DGX with Broad Market Indices
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 1.57% | 0.62% | 15.16% | 1.22% |
US NASDAQ 100 | QQQ | 3.22% | 2.03% | 19.29% | 3.55% |
US Dow Jones Industrial 30 | DIA | 0.25% | 0.31% | 16.54% | 4.90% |
German DAX 40 | DBXD | 0.67% | -1.29% | 19.01% | 8.80% |
UK FTSE 100 | ISFU | -0.32% | -2.16% | 9.52% | 5.24% |
Shanghai Shenzhen CSI 300 | CSI 300 | 0.11% | 6.42% | 28.11% | 34.31% |
Hongkong Hang Seng | HSI | -0.35% | -0.66% | 21.33% | 29.24% |
Japan Nikkei 225 | EXX7 | 4.55% | -1.57% | 31.97% | 17.54% |
India NIFTY 50 | INDA | -0.47% | 1.50% | 13.40% | -0.91% |
Brasil Bovespa | EWZ | -0.86% | -2.77% | 30.35% | 23.16% |
DGX Quest Diagnostics vs. Sectors
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 1.50% | 3.52% | 14.47% | -1.12% |
Consumer Discretionary | XLY | -0.05% | -1.28% | 19.85% | 17.31% |
Consumer Staples | XLP | -3.15% | -1.96% | 10.02% | 5.25% |
Energy | XLE | 3.20% | 5.23% | 21.52% | 25.54% |
Financial | XLF | 0.60% | -2.61% | 11.94% | -7.34% |
Health Care | XLV | -0.50% | -0.26% | 15.61% | 5.75% |
Industrial | XLI | 1.67% | 0.96% | 17.63% | 2.33% |
Materials | XLB | 2.09% | 2.52% | 19.74% | 11.75% |
Real Estate | XLRE | -2.75% | -0.90% | 10.07% | 0.03% |
Technology | XLK | 4.88% | 2.45% | 23.09% | 5.08% |
Utilities | XLU | -2.07% | -0.06% | -0.28% | -0.36% |
Aerospace & Defense | XAR | 2.64% | 0.11% | 17.37% | -2.94% |
Biotech | XBI | 2.11% | 1.91% | 25.32% | 0.79% |
Homebuilder | XHB | 1.83% | 0.69% | 14.00% | -14.20% |
Retail | XRT | 2.41% | 4.62% | 25.09% | 4.75% |
Does Quest Diagnostics outperform its market, is DGX a Sector Leader?
Yes, over the last 12 months Quest Diagnostics (DGX) made 23.40%, while its related Sector, the Health Care Sector SPDR Fund (XLV) made 17.65%.
Over the last 3 months DGX made 7.79%, while XLV made 5.66%.
Yes, over the last 12 months Quest Diagnostics (DGX) made 23.40%, while its related Sector, the Health Care Sector SPDR Fund (XLV) made 17.65%.
Over the last 3 months DGX made 7.79%, while XLV made 5.66%.
Period | DGX | XLV | S&P 500 |
---|---|---|---|
1 Month | 4.11% | 4.37% | 3.49% |
3 Months | 7.79% | 5.66% | 1.39% |
12 Months | 23.40% | 17.65% | 22.18% |